Related Experiment Video
Updated: Jan 28, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis
Alia Z Al-Mousawi1, Sam P Gurney1, Alice R Lorenzi2
1Birmingham Neuro-Ophthalmology, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, B15 2WB, UK.
Insights
Giant cell arteritis (GCA) management is improving with new targeted therapies like tocilizumab, an IL-6 inhibitor, reducing steroid side effects. Advances in diagnostics and rapid access also enhance patient outcomes.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Giant cell arteritis (GCA) pathophysiology is increasingly understood, driving new therapeutic strategies.
- Glucocorticoid (GC) associated morbidity is a significant concern for GCA patients and clinicians.
- Advances in diagnostics and patient care pathways are crucial for managing GCA.
Purpose of the Study:
- To review the evolving understanding of GCA pathophysiology and its impact on clinical management.
- To highlight novel targeted therapies, including IL-6 receptor inhibitors, for GCA treatment.
- To discuss improvements in diagnostic tools and patient access impacting GCA outcomes.
Main Methods:
- Review of recent randomized controlled trials for targeted GCA therapies.
- Analysis of emerging research on GCA pathophysiology.
- Assessment of the role of advanced imaging and rapid access pathways in GCA care.
Main Results:
- Tocilizumab, an IL-6 receptor inhibitor, is the first licensed targeted therapy for GCA.
- New targeted treatments are emerging based on improved understanding of disease mechanisms.
- Ultrasound and rapid access pathways are improving diagnosis and patient outcomes.
Conclusions:
- Enhanced understanding of GCA pathophysiology is leading to effective targeted therapies.
- Reducing cumulative glucocorticoid use is a key goal in GCA management.
- Integrated care approaches combining novel therapies and improved diagnostics enhance long-term outcomes for GCA patients.
Abstract:
Improving understanding of the underlying pathophysiology of giant cell arteritis (GCA) is transforming clinical management by identifying novel avenues for targeted therapies. One key area of concern for both clinicians and patients with GCA is glucocorticoid (GC) morbidity. The first randomised controlled trials of targeted treatment to reduce cumulative GC use in GCA have been published, with tocilizumab, an interleukin (IL)-6 receptor inhibitor, now the first ever licensed treatment for GCA. Further potential therapies are emerging owing to our enhanced understanding of the pathophysiology of the disease. Other improvements in the care of our patients are rapid access pathways and imaging techniques, such as ultrasound, which are becoming part of modern rheumatology practice in the UK, Europe and beyond. These have been highlighted in the literature to reduce delay in diagnosis and improve long-term outcomes for those investigated for GCA.
Related Concept Videos
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Pathophysiology of Vomiting
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

